- Home
- NMIH vs TNGX Comparison
NMIH vs TNGX Comparison
Compare NMIH & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | TNGX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMIH | TNGX |
|---|---|---|
| Price | $38.64 | $19.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $42.75 | $20.00 |
| AVG Volume (30 Days) | 331.2K | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.06 | ★ 26.89 |
| EPS | ★ 4.92 | N/A |
| Revenue | ★ $706,440,000.00 | $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.34 | N/A |
| P/E Ratio | $7.99 | ★ N/A |
| Revenue Growth | 8.52 | ★ 48.29 |
| 52 Week Low | $32.71 | $1.04 |
| 52 Week High | $43.20 | $22.20 |
Technical Indicators
Market Signals| Indicator | NMIH | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 57.07 |
| Support Level | $38.52 | $6.54 |
| Resistance Level | $38.93 | $22.01 |
| Average True Range (ATR) | 0.75 | 1.29 |
| MACD | 0.27 | -0.25 |
| Stochastic Oscillator | 68.00 | 33.33 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.